Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin in Cirrhotic Gastroesophageal Variceal Hemorrhage
NCT02991612Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Nov 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rifaximin in Gastrointestinal Bleeding (GIB) and esophageal and gastric varices, sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Incidence of all clinical adverse events at 8 weeks. Started Nov 2016; status: completed.
02
Drugs
rifaximin
03
Conditions
Gastrointestinal Bleeding (GIB)esophageal and gastric varices
Beyond the preview
Go deeper on NCT02991612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02991612.